BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS: Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabetic rats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS: Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was able to prevent hypertrophic alterations and reduce protein carbonylation in the cardiac tissue. CONCLUSIONS: Oxidative protein modification, together with cardiac hypertrophy and high generation of *NO and ONOO-, are important early events in the development of cardiovascular complications in diabetes. Aminoguanidine could prevent hypertrophy through inhibition of production of nonenzymatic glycation products rather than via inhibition of *NO production. Copyright 2004 John Wiley & Sons, Ltd.
BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS:Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabeticrats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS:Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was able to prevent hypertrophic alterations and reduce protein carbonylation in the cardiac tissue. CONCLUSIONS: Oxidative protein modification, together with cardiac hypertrophy and high generation of *NO and ONOO-, are important early events in the development of cardiovascular complications in diabetes. Aminoguanidine could prevent hypertrophy through inhibition of production of nonenzymatic glycation products rather than via inhibition of *NO production. Copyright 2004 John Wiley & Sons, Ltd.
Authors: N Nass; B Bartling; A Navarrete Santos; R J Scheubel; J Börgermann; R E Silber; A Simm Journal: Z Gerontol Geriatr Date: 2007-10 Impact factor: 1.281
Authors: Fernando Magdaleno; Chuck Christopher Blajszczak; Claudia Lisette Charles-Niño; Alma Marlene Guadrón-Llanos; Alan Omar Vázquez-Álvarez; Alejandra Guillermina Miranda-Díaz; Natalia Nieto; María Cristina Islas-Carbajal; Ana Rosa Rincón-Sánchez Journal: Exp Ther Med Date: 2019-08-20 Impact factor: 2.447
Authors: Christian Solís-Calero; Joaquín Ortega-Castro; Alfonso Hernández-Laguna; Francisco Muñoz Journal: J Mol Model Date: 2014-04-05 Impact factor: 1.810